ATRC says revenue and profitability are ahead of long-term targets
ATRC says revenue and profitability are ahead of long-term targets, citing strong pain management growth, clinical trial progress and product innovation. It also highlights LEAPS and BoxX-NoAF advancing ahead of schedule, plus new device launches and international expansion.
Revenue and profitability are ahead of long-term targets, supported by strong growth in pain management, clinical trial progress and product innovation. Major clinical trials including LEAPS and BoxX-NoAF are advancing ahead of schedule, while new device launches and international expansion are supporting future growth.